Benzinga · Nov 9, 2026
B. Riley Securities Reiterates Buy on Agenus, Raises Price Target to $16
B. Riley Securities analyst Mayank Mamtani reiterates Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $14 to $16.
NASDAQ · AGEN
Healthcare · Biotechnology
$6.29
Down-$0.44 (-6.54%)
Updated Nov 17, 2026, 2:08 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AGEN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
AGEN closed at $6.29 after 21 trading sessions, up 1.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $6.60 | $6.6648 | $6.245 | $6.29 | 568.27K |
| Nov 13, 2026 | $6.97 | $6.97 | $6.50 | $6.73 | 465.15K |
| Nov 12, 2026 | $7.07 | $7.085 | $6.775 | $6.87 | 499.05K |
| Nov 11, 2026 | $7.13 | $7.29 | $7.02 | $7.22 | 430.51K |
| Nov 10, 2026 | $7.10 | $7.13 | $6.635 | $7.02 | 691.63K |
| Nov 9, 2026 | $7.32 | $7.65 | $7.11 | $7.15 | 840.87K |
| Nov 6, 2026 | $6.54 | $7.20 | $6.3715 | $7.15 | 873.56K |
| Nov 5, 2026 | $6.81 | $6.93 | $6.11 | $6.44 | 1.33M |
| Nov 4, 2026 | $6.99 | $7.06 | $6.85 | $6.97 | 729.96K |
| Nov 3, 2026 | $6.59 | $6.86 | $6.5001 | $6.67 | 499.04K |
| Nov 2, 2026 | $6.85 | $6.855 | $6.43 | $6.53 | 595.56K |
| Oct 30, 2026 | $6.87 | $7.09 | $6.69 | $6.84 | 564.49K |
| Oct 29, 2026 | $7.13 | $7.30 | $6.942 | $7.09 | 625.39K |
| Oct 28, 2026 | $6.51 | $7.14 | $6.47 | $7.13 | 744.3K |
| Oct 27, 2026 | $6.13 | $6.675 | $6.11 | $6.65 | 839.02K |
| Oct 26, 2026 | $6.49 | $6.50 | $6.14 | $6.16 | 687.89K |
| Oct 23, 2026 | $6.36 | $6.50 | $6.16 | $6.33 | 510.51K |
| Oct 22, 2026 | $6.32 | $6.53 | $6.2364 | $6.51 | 553.95K |
| Oct 21, 2026 | $6.43 | $6.54 | $6.31 | $6.40 | 789.68K |
| Oct 20, 2026 | $6.10 | $6.58 | $6.05 | $6.42 | 827.18K |
| Oct 19, 2026 | $6.13 | $6.30 | $6.055 | $6.18 | 734.96K |
The latest Smart Investors Daily articles mentioning AGEN.
Company
Market Activity
Research & News
AGEN research
Company profile and research snapshot.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 9, 2026 | B. Riley Securities | Buy | — |
| Oct 26, 2026 | Chardan Capital | Buy | — |
| Oct 22, 2026 | Chardan Capital | Buy | — |
| Oct 5, 2026 | Chardan Capital | Buy | — |
| Sep 28, 2026 | Rodman & Renshaw | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 9, 2026
B. Riley Securities analyst Mayank Mamtani reiterates Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $14 to $16.
Yahoo · Nov 6, 2026
AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.
Yahoo · Nov 6, 2026
LEXINGTON, Mass., November 06, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were pres
SeekingAlpha · Nov 6, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning AGEN.